VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
NTRANatera, Inc.
$231.41$33.1B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

NTRA logoNatera, Inc.(NTRA)Earnings, Financials & Key Ratios

NTRA•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryMolecular and Genetic Diagnostics
AboutNatera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.Show more
  • Revenue$2.31B+35.9%
  • EBITDA-$264M-38.0%
  • Net Income-$208M-9.3%
  • EPS (Diluted)-1.52+0.7%
  • Gross Margin64.85%+7.6%
  • EBITDA Margin-11.45%-1.5%
  • Operating Margin-13.44%-2.6%
  • Net Margin-9.03%+19.6%
  • ROE-14.32%+26.3%

NTRA Key Insights

Natera, Inc. (NTRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 42.6%

✗Weaknesses

  • ✗Expensive at 18.5x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when NTRA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NTRA Price & Volume

Natera, Inc. (NTRA) stock price & volume — 10-year historical chart

Loading chart...

NTRA Growth Metrics

Natera, Inc. (NTRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years28.33%
5 Years42.61%
3 Years41.14%
TTM36.59%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-19.26%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-10.88%

Return on Capital

10 Years-53.32%
5 Years-36.33%
3 Years-25.56%
Last Year-18.32%

NTRA Recent Earnings

Natera, Inc. (NTRA) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.56-3.3%
$0.54
Rev
$697M+12.9%
$617M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.35+168.3%
$0.51
Rev
$666M+10.2%
$604M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.64-65.9%
$0.39
Rev
$592M+15.3%
$513M
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$0.74-20.2%
$0.62
Rev
$547M+14.8%
$476M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.56vs $0.54-3.3%
$697Mvs $617M+12.9%
Q1 2026Feb 26, 2026
$0.35vs $0.51+168.3%
$666Mvs $604M+10.2%
Q4 2025Nov 6, 2025
$0.64vs $0.39-65.9%
$592Mvs $513M+15.3%
Q3 2025Aug 7, 2025
$0.74vs $0.62-20.2%
$547Mvs $476M+14.8%
Based on last 12 quarters of dataView full earnings history →

NTRA Peer Comparison

Natera, Inc. (NTRA) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
EXAS logoEXASExact Sciences CorporationDirect Competitor20.02B104.91-95.3717.69%-6.4%-8.66%1.05
ILMN logoILMNIllumina, Inc.Direct Competitor24.6B161.9329.71-0.78%19.43%32.84%0.94
CGEN logoCGENCompugen Ltd.Direct Competitor190.05M2.015.29161.14%48.57%55.68%0.03
MYRG logoMYRGMYR Group Inc.Product Competitor7.18B461.1061.248.79%3.71%22.14%0.16
PACB logoPACBPacific Biosciences of California, Inc.Product Competitor434.84M1.40-0.773.89%-80.34%-488.45%141.98
PRME logoPRMEPrime Medicine, Inc.Product Competitor583.39M3.23-2.3955.28%-49.18%-188.82%0.96
CDNA logoCDNACareDx, IncProduct Competitor1.35B26.18-65.4513.79%-1.98%-2.61%0.06
TMO logoTMOThermo Fisher Scientific Inc.Supply Chain172.66B464.6126.193.91%15.18%13.23%0.76

Compare NTRA vs Peers

Natera, Inc. (NTRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXAS

Most directly comparable listed peer for NTRA.

Scale Benchmark

vs TMO

Larger-name benchmark to compare NTRA against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXAS, ILMN, CGEN, MYRG

NTRA Income Statement

Natera, Inc. (NTRA) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
210.94M257.65M302.33M391M625.49M820.22M1.08B1.7B2.31B2.5B
Revenue Growth %
-2.83%22.15%17.34%29.33%59.97%31.13%31.99%56.75%35.9%36.59%
Cost of Goods Sold
139.6M166.06M175.47M203.62M318.42M456.26M589.83M673.75M810.63M871.22M
COGS % of Revenue
66.18%64.45%58.04%52.08%50.91%55.63%54.48%39.7%35.15%-
Gross Profit
71.34M▲ 0%
91.6M▲ 28.4%
126.86M▲ 38.5%
187.38M▲ 47.7%
307.07M▲ 63.9%
363.97M▲ 18.5%
492.74M▲ 35.4%
1.02B▲ 107.6%
1.5B▲ 46.2%
1.63B▲ 0%
Gross Margin %
33.82%35.55%41.96%47.92%49.09%44.37%45.52%60.3%64.85%65.16%
Gross Profit Growth %
-12.46%28.39%38.49%47.71%63.87%18.53%35.38%107.65%46.16%-
Operating Expenses
205.37M206.23M243.15M403.66M775.24M905.01M938.99M1.25B1.81B1.95B
OpEx % of Revenue
97.36%80.04%80.42%103.24%123.94%110.34%86.74%73.4%78.29%-
Selling, General & Admin
155.31M154.87M206.18M303.63M511.03M588.59M618.31M841.31M1.18B1.24B
SG&A % of Revenue
73.63%60.11%68.2%77.65%81.7%71.76%57.11%49.58%51.05%-
Research & Development
50.06M51.35M51.36M100.03M264.21M316.42M320.68M404.14M624.11M705.73M
R&D % of Revenue
23.73%19.93%16.99%25.58%42.24%38.58%29.62%23.82%27.06%-
Other Operating Expenses
00-14.39M000004.03M2.46M
Operating Income
-134.03M▲ 0%
-114.63M▲ 14.5%
-116.29M▼ 1.4%
-216.28M▼ 86.0%
-468.17M▼ 116.5%
-541.04M▼ 15.6%
-446.25M▲ 17.5%
-222.29M▲ 50.2%
-309.91M▼ 39.4%
-324.25M▲ 0%
Operating Margin %
-63.54%-44.49%-38.46%-55.31%-74.85%-65.96%-41.22%-13.1%-13.44%-12.97%
Operating Income Growth %
-38.91%14.47%-1.45%-85.99%-116.47%-15.56%17.52%50.19%-39.41%-
EBITDA
-126.88M-107.13M-108.56M-207.66M-456.92M-510.57M-407.63M-191.33M-264.02M-313.26M
EBITDA Margin %
-60.15%-41.58%-35.91%-53.11%-73.05%-62.25%-37.65%-11.28%-11.45%-12.53%
EBITDA Growth %
-40.5%15.57%-1.33%-91.29%-120.03%-11.74%20.16%53.06%-37.99%-61.46%
D&A (Non-Cash Add-back)
7.14M7.5M7.73M8.61M11.25M30.47M38.62M30.97M010.99M
EBIT
-132.96M-114.63M-112.14M-214.56M-462.79M-537.5M-421.89M-179.05M-264.02M-285.62M
Net Interest Income
-1.83M-13.21M-6.54M-7.52M-2.92M-5.78M11.71M32.56M-4.07M26.57M
Interest Income
2.38M04.15M7.56M5.38M3.54M24.35M43.25M034.9M
Interest Expense
4.21M10.48M10.69M15.08M8.3M9.32M12.64M10.69M4.07M8.33M
Other Income/Expense
-1.83M-13.21M-6.54M-13.37M-2.92M-5.78M11.71M32.56M41.82M38.12M
Pretax Income
-135.86M▲ 0%
-127.83M▲ 5.9%
-122.83M▲ 3.9%
-229.65M▼ 87.0%
-471.1M▼ 105.1%
-546.82M▼ 16.1%
-434.53M▲ 20.5%
-189.73M▲ 56.3%
-268.09M▼ 41.3%
-286.13M▲ 0%
Pretax Margin %
-64.41%-49.61%-40.63%-58.73%-75.32%-66.67%-40.14%-11.18%-11.63%-11.44%
Income Tax
454K321K2M98K618K978K271K695K-59.93M-59.82M
Effective Tax Rate %
-0.33%-0.25%-1.63%-0.04%-0.13%-0.18%-0.06%-0.37%22.35%20.91%
Net Income
-136.31M▲ 0%
-128.15M▲ 6.0%
-124.83M▲ 2.6%
-229.74M▼ 84.0%
-471.72M▼ 105.3%
-547.8M▼ 16.1%
-434.8M▲ 20.6%
-190.43M▲ 56.2%
-208.16M▼ 9.3%
-226.31M▲ 0%
Net Margin %
-64.62%-49.74%-41.29%-58.76%-75.42%-66.79%-40.16%-11.22%-9.03%-9.05%
Net Income Growth %
-42.34%5.99%2.6%-84.05%-105.32%-16.13%20.63%56.2%-9.31%-19.26%
Net Income (Continuing)
-137.63M-128.15M-124.83M-229.74M-471.72M-547.8M-434.8M-190.43M-208.16M-226.31M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-2.54▲ 0%
-2.22▲ 12.6%
-1.79▲ 19.4%
-2.84▼ 58.7%
-5.21▼ 83.5%
-5.57▼ 6.9%
-3.78▲ 32.1%
-1.53▲ 59.5%
-1.52▲ 0.7%
-1.60▲ 0%
EPS Growth %
-36.56%12.6%19.37%-58.66%-83.45%-6.91%32.14%59.52%0.65%-10.88%
EPS (Basic)
-2.56-2.22-1.79-2.84-5.21-5.57-3.78-1.53-1.52-
Diluted Shares Outstanding
53.6M57.85M69.56M81.01M90.56M98.41M115M124.72M136.72M141.5M
Basic Shares Outstanding
53.31M57.73M69.56M81.01M90.56M98.41M115M124.72M136.72M141.5M
Dividend Payout Ratio
----------

NTRA Balance Sheet

Natera, Inc. (NTRA) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
180.63M240.52M523.17M862.66M1.09B1.21B1.26B1.38B1.5B1.65B
Cash & Short-Term Investments
118.87M153.87M440.99M737.27M914.28M898.39M878.98M968.28M1.08B1.09B
Cash Only
12.62M46.41M61.93M48.67M84.39M466.09M642.1M945.59M1.08B1.09B
Short-Term Investments
106.25M107.46M379.06M688.61M829.9M432.3M236.88M22.69M00
Accounts Receivable
44.09M62.22M53.35M78.56M122.07M244.38M278.29M314.17M296.53M417.6M
Days Sales Outstanding
76.2988.1564.4173.3471.24108.7593.8367.5846.9347.79
Inventory
9M13.63M12.39M20.03M26.91M35.41M40.76M44.74M68.44M70.72M
Days Inventory Outstanding
23.5329.9725.7835.9130.8528.3225.2224.2430.8227.03
Other Current Assets
59K4.6M55K187K228K33.63M60.52M48.63M55.83M75.56M
Total Non-Current Assets
33.99M27.65M59.49M69.49M143.35M182.66M183.15M284.92M1.01B962.59M
Property, Plant & Equipment
29.67M24.34M47.01M54.75M124.53M164.33M167.75M248.19M349.73M403.37M
Fixed Asset Turnover
7.11x10.59x6.43x7.14x5.02x4.99x6.45x6.84x6.59x7.46x
Goodwill
00000000141.07M140.86M
Intangible Assets
00000000373.71M367.36M
Long-Term Investments
0000000000
Other Non-Current Assets
4.32M3.32M12.48M14.74M18.82M18.33M15.4M36.72M36.9M51M
Total Assets
214.61M▲ 0%
268.17M▲ 25.0%
582.66M▲ 117.3%
932.15M▲ 60.0%
1.24B▲ 32.6%
1.39B▲ 12.8%
1.44B▲ 3.4%
1.66B▲ 15.2%
2.51B▲ 51.0%
2.61B▲ 0%
Asset Turnover
0.98x0.96x0.52x0.42x0.51x0.59x0.75x1.02x0.92x1.15x
Asset Growth %
1.87%24.96%117.27%59.98%32.65%12.78%3.39%15.19%51.02%132.25%
Total Current Liabilities
105.56M113.98M179.87M199.05M218.96M310.5M307.27M344.05M441.23M558.26M
Accounts Payable
8.53M14.59M8.6M8.1M27.21M31.15M15M34.92M33.16M62.4M
Days Payables Outstanding
22.332.0617.914.5131.1924.929.2818.9214.9318.74
Short-Term Debt
50.11M50.15M50.12M50.05M50.05M80.35M80.4M80.36M95.9M95.13M
Deferred Revenue (Current)
1.42M4.13M56.02M50.13M7.4M10.78M16.61M19.75M24.91M105.11M
Other Current Liabilities
19.04M22.68M25.5M47.74M58.15M62.96M69.1M73.39M186.29M210.68M
Current Ratio
1.71x2.11x2.91x4.33x4.99x3.90x4.10x4.00x3.39x2.96x
Quick Ratio
1.63x1.99x2.84x4.23x4.87x3.79x3.96x3.87x3.24x2.83x
Cash Conversion Cycle
77.5286.0572.2994.7370.9112.16109.7772.962.8256.08
Total Non-Current Liabilities
83.64M122.03M124.07M246.86M364.23M378.23M369.1M121.27M354.4M282.12M
Long-Term Debt
73.06M73.36M73.66M202.49M280.39M281.65M282.94M000
Capital Lease Obligations
0026.3M21.25M61.04M76.58M67.03M96.59M118.47M470.55M
Deferred Tax Liabilities
00000000110.39M111.09M
Other Non-Current Liabilities
10.57M8.61M310K320K1.48M000108.47M119.47M
Total Liabilities
189.2M236.01M303.94M445.92M583.18M688.73M676.37M465.31M795.62M840.38M
Total Debt
123.18M123.51M155.81M281.09M397.23M446.22M441.99M187.12M214.38M240.08M
Net Debt
110.56M77.1M93.89M232.43M312.85M-19.87M-200.1M-758.47M-861.76M-847.85M
Debt / Equity
4.85x3.84x0.56x0.58x0.61x0.63x0.58x0.16x0.13x0.14x
Debt / EBITDA
----------0.77x
Net Debt / EBITDA
---------2.71x
Interest Coverage
-31.56x-10.94x-10.49x-14.23x-55.72x-57.68x-33.38x-16.76x-64.89x-34.29x
Total Equity
25.42M▲ 0%
32.16M▲ 26.5%
278.71M▲ 766.6%
486.24M▲ 74.5%
653.3M▲ 34.4%
705.74M▲ 8.0%
765.33M▲ 8.4%
1.2B▲ 56.2%
1.71B▲ 43.2%
1.77B▲ 0%
Equity Growth %
-76.13%26.54%766.58%74.46%34.36%8.03%8.44%56.2%43.25%177.86%
Book Value per Share
0.470.564.016.007.217.176.669.5812.5212.54
Total Shareholders' Equity
25.42M32.16M278.71M486.24M653.3M705.74M765.33M1.2B1.71B1.77B
Common Stock
6K7K8K9K10K11K11K12K14K14K
Retained Earnings
-446.38M-574.53M-699.17M-929.32M-1.39B-1.94B-2.38B-2.57B-2.78B-2.86B
Treasury Stock
0000000000
Accumulated OCI
-766K-552K919K4.26M-2.29M-16.36M-3.08M-344K-258K-202K
Minority Interest
0000000000

NTRA Cash Flow Statement

Natera, Inc. (NTRA) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-97.83M-70.58M-63.44M-182.51M-335.24M-431.5M-246.96M135.66M215.3M211.02M
Operating CF Margin %
-46.38%-27.39%-20.99%-46.68%-53.6%-52.61%-22.81%7.99%9.34%-
Operating CF Growth %
-32.1%27.85%10.11%-187.67%-83.68%-28.72%42.77%154.93%58.7%886.46%
Net Income
-137.63M-128.15M-124.83M-229.74M-471.72M-547.8M-434.8M-190.43M-208.16M-226.31M
Depreciation & Amortization
7.14M7.5M7.73M8.61M11.25M16.7M24.1M30.97M43.48M54.47M
Stock-Based Compensation
11.4M14.2M28.62M50.17M115.22M152.38M191.81M274.43M0184M
Deferred Taxes
00000000-60.8M-60.8M
Other Non-Cash Items
1.65M8.72M-2.17M27.58M55.61M30.36M19.89M18.55M369.93M215.05M
Working Capital Changes
19.61M27.16M27.2M-39.13M-45.6M-83.15M-47.95M2.14M70.84M44.62M
Change in Receivables
6.32M-18.09M2.42M-25.83M-43.51M-122.31M-33.9M-35.88M20.75M-96.25M
Change in Inventory
-3.09M-4.9M917K-7.47M-6.88M-8.5M-5.35M-3.98M-20.87M-17.53M
Change in Payables
217K3.78M-6.26M-118K19.22M5.46M-15.46M13.21M753K20.25M
Cash from Investing
13.78M-5.16M-266.35M-331.46M-205.19M330.34M168.5M137.62M-132.21M-147.53M
Capital Expenditures
-9.87M-3.88M-4.97M-19.6M-41.03M-47.7M-39.2M-66.42M-139.19M-127.01M
CapEx % of Revenue
4.68%1.51%1.64%5.01%6.56%5.82%3.62%3.91%6.04%5.08%
Acquisitions
009.68M00000-16.02M-16.02M
Investments
----------
Other Investing
0000-8.56M00-10.49M0-12.5M
Cash from Financing
80.37M113.72M340.77M500.85M576.19M482.64M254.46M30.2M47.46M50.67M
Debt Issued (Net)
75M00199.56M030M0-82K00
Equity Issued (Net)
5.66M113.72M340.77M301.29M576.19M452.64M254.46M30.29M47.46M48.74M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
-287K000000001.94M
Net Change in Cash
-3.67M▲ 0%
37.98M▲ 1135.2%
10.98M▼ 71.1%
-13.13M▼ 219.6%
35.76M▲ 372.4%
381.48M▲ 966.8%
176M▼ 53.9%
303.49M▲ 72.4%
130.55M▼ 57.0%
114.16M▲ 0%
Free Cash Flow
-106.66M▲ 0%
-74.46M▲ 30.2%
-68.41M▲ 8.1%
-202.12M▼ 195.4%
-376.27M▼ 86.2%
-479.2M▼ 27.4%
-286.15M▲ 40.3%
69.24M▲ 124.2%
109.11M▲ 57.6%
92.01M▲ 0%
FCF Margin %
-50.56%-28.9%-22.63%-51.69%-60.16%-58.42%-26.43%4.08%4.73%3.68%
FCF Growth %
-9.91%30.19%8.12%-195.44%-86.16%-27.36%40.28%124.2%57.58%8%
FCF per Share
-1.99-1.29-0.98-2.49-4.15-4.87-2.490.560.800.65
FCF Conversion (FCF/Net Income)
0.72x0.55x0.51x0.79x0.71x0.79x0.57x-0.71x-1.03x-0.41x
Interest Paid
3.57M7.91M12.46M3.3M7.08M8.06M11.35M7.9M01.04M
Taxes Paid
177K332K2.15M67K283K549K295K1.31M00

NTRA Key Ratios

Natera, Inc. (NTRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-206.7%-445.14%-80.31%-60.07%-82.79%-80.62%-59.11%-19.42%-14.32%-15.13%
Return on Invested Capital (ROIC)
-72.63%-70.11%-36.2%-29.73%-41.68%-49.13%-53.5%-33.27%-36.1%-37.2%
Gross Margin
33.82%35.55%41.96%47.92%49.09%44.37%45.52%60.3%64.85%65.16%
Net Margin
-64.62%-49.74%-41.29%-58.76%-75.42%-66.79%-40.16%-11.22%-9.03%-9.05%
Debt / Equity
4.85x3.84x0.56x0.58x0.61x0.63x0.58x0.16x0.13x0.14x
Interest Coverage
-31.56x-10.94x-10.49x-14.23x-55.72x-57.68x-33.38x-16.76x-64.89x-34.29x
FCF Conversion
0.72x0.55x0.51x0.79x0.71x0.79x0.57x-0.71x-1.03x-0.41x
Revenue Growth
-2.83%22.15%17.34%29.33%59.97%31.13%31.99%56.75%35.9%36.59%
Related:NTRA Dividend History·NTRA Revenue History·NTRA Price History·NTRA P/E History·NTRA Financial Ratios·NTRA Institutional Holders

NTRA SEC Filings & Documents

Natera, Inc. (NTRA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Apr 1, 2026·SEC

Material company update

Feb 26, 2026·SEC

10-K Annual Reports

1
FY 2026

Feb 27, 2026·SEC

10-Q Quarterly Reports

4
FY 2026

May 8, 2026·SEC

FY 2025

Nov 7, 2025·SEC

FY 2025

Aug 8, 2025·SEC

NTRA Frequently Asked Questions

Natera, Inc. (NTRA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Natera, Inc. (NTRA) reported $2.50B in revenue for fiscal year 2025. This represents a 17450% increase from $14.3M in 2012.

Natera, Inc. (NTRA) grew revenue by 35.9% over the past year. This is strong growth.

Natera, Inc. (NTRA) reported a net loss of $226.3M for fiscal year 2025.

Dividend & Returns

Natera, Inc. (NTRA) has a return on equity (ROE) of -14.3%. Negative ROE indicates the company is unprofitable.

Natera, Inc. (NTRA) generated $92.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in NTRA back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →

How much would $100/month in NTRA be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →